Altre lingue Takeda Pharmaceutical Company Limited OTC Markets

Azioni

TKPHF

JP3463000004

Tempo differito OTC Markets Altri mercati azionari 19:54:51 26/06/2024			Variaz. 5gg	Var. 1 gen.
25,69 ^USD	-0,85%		+0,75%	-10,58%

25/06	Il CDC statunitense avverte gli operatori sanitari dell'aumento dei casi di dengue	RE
25/06	Il farmaco antitumorale di Takeda ottiene l'approvazione della Commissione Europea	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Takeda Announces the Publication of its Annual Report on Form 20-F for FY2023	14:31
Takeda anuncia el nombramiento de nuevos cargos directivos	05:58
Takeda kündigt neue Besetzung der Direktorenposten an	01:44
Takeda annonce de nouvelles nominations de directeurs	01:26
TAKEDA PHARMACEUTICAL : Form 6 K	26/06
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K	26/06
Takeda Announces New Assignments of Directors	26/06
US CDC alerts healthcare providers of increase in dengue cases	25/06
Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Takeda Pharmaceutical Company Limited OTC Markets

Azioni

TKPHF

JP3463000004

Altre lingue

Filtri